Difference between revisions of "Team:Fudan-CHINA/Applied Design"

 
(4 intermediate revisions by 2 users not shown)
Line 4: Line 4:
  
  
−
<div class="column full_size">
+
−
<h1>Applied Design</h1>
+
 +
<!--start---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------->
 +
 +
 
 +
 
 +
<!---------------------------------------------------------------------------------------------------------------------------------------------------->
 +
 +
<div id="firstDiv">
 +
<img src="https://static.igem.org/mediawiki/2018/1/1f/T--Fudan-CHINA--dsbgImg.jpg" />
 +
<div class="fiName">Applied Design</div>
 +
<div class="pSentence">
 +
"What we do for ourselves dies with us. What we do for others and the world remains and is immortal."
 +
</div>
 
</div>
 
</div>
−
<div class="clear"></div>
 
  
 +
<!---------------------------------------------------------------------------------------------------------------------------------------------------->
 +
 +
<div class="mainWords">
 +
  
−
<div class="column two_thirds_size">
+
<div class="mainContents">
−
<h3>Best Applied Design Special Prize</h3>
+
Our project provides a brand-new solution for cell therapy of cancer – to deal with free extracellular ligands instead of cell surface antigens, which are obviously difficult to reach because of the barrier of tumour microenvironment.
 +
<br><br>
 +
For clinical application, the STEP system can be used to equip cells for cancer therapy. Stable STEP cell line can be produced with T cells extracted from patients. Then it can be reinfused into the blood to monitor level of target ligand and to produce specific drug in real time (Figure 1). In this way we can release patients from the pain of radiotherapy or chemotherapy, while inhibit tumour development in a more efficient way.
 +
<div class="imgState">
 +
<img src="https://static.igem.org/mediawiki/2018/3/30/T--Fudan-CHINA--AppDes01.png" style="width:70%;">
 +
<div>
 +
<span class="figureNum">Figure 1.</span>
 +
</div>
 +
</div>
 +
<br>
 +
One of the biggest advantage STEP has over other treatments is its modifiable upstream and downstream. For ligand recognition, we’ve already developed STEP for VEGF and for D-Dimer, the former for broad-spectrum scanning for tumour and the latter more specific for NSCLC. Both systems will be ready to use after overall test and optimisation in T cells. Our users can also select one or more tumour marker for a particular cancer type, clone the scFv or other kinds of binding domains to the extracellular domain and test the output. The binding affinity can always be increased, or in some cases decreased, with the help of our user-friendly assistant software and Rosetta. If there’s no sequence of binding domain available, we can also help you design a high-affinity scFv in silico with these softwares (Figure 2). As a result, we can literally achieve recognisation of any customer appointed ligands with our STEP system.
 +
<div class="imgState">
 +
<img src="https://static.igem.org/mediawiki/2018/5/53/T--Fudan-CHINA--AppDes02.png" style="width:100%;">
 +
<div>
 +
<span class="figureNum">Figure 2.</span>
 +
</div>
 +
</div>
 +
<br>
 +
Another superiority of STEP is the tuneable downstream and the changeable reporter. The curve of downstream gene expression can be easily modified either by simply changing a transcription factor, or by altering the binding affinity between the DNA sequence and the transcription factor. The reporter, on the other hand, can be any kind of drugs for unique situations of different patients.
 +
<br><br>
 +
Being a highly modular transducer engineering platform and able to meet needs of various kinds of cancer patients, STEP will definitely be the best choice for cell therapy.
  
−
<p>This is a prize for the team that has developed a synbio product to solve a real world problem in the most elegant way. The students will have considered how well the product addresses the problem versus other potential solutions, how the product integrates or disrupts other products and processes, and how its lifecycle can more broadly impact our lives and environments in positive and negative ways.
+
−
<br><br>
+
</div>
−
To compete for the <a href="https://2018.igem.org/Judging/Awards">Best Applied Design prize</a>, please describe your work on this page and also fill out the description on the <a href="https://2018.igem.org/Judging/Judging_Form">judging form</a>.
+
−
<br><br>
+
−
You must also delete the message box on the top of this page to be eligible for this prize.
+
−
</p>
+
 
</div>
 
</div>
  
 +
 +
 +
<!--end--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------->
  
−
<div class="column third_size">
+
−
<div class="highlight decoration_A_full">
+
<!--TEMPLATE:contact-->
−
<h3>Inspiration</h3>
+
−
<p>Take a look at what some teams accomplished for this prize.</p>
+
<div id="contactUs">
−
<ul>
+
<img width="8%">
−
<li><a href="https://2016.igem.org/Team:NCTU_Formosa/Design">2016 NCTU Formosa</a></li>
+
<div class="cuCol" id="cuCol1" style="width: 17%;">
−
<li><a href="https://2016.igem.org/Team:HSiTAIWAN/Product?locationId=Design">2016 HSiTAIWAN</a></li>
+
<h1 class="cuH1"><i class="fa fa-link"></i>&#160;&#160;Useful Links</h1>
−
<li><a href="https://2016.igem.org/Team:Pasteur_Paris/Design">2016 Pasteur Paris</a></li>
+
<hr width="50%">
−
</ul>
+
<br/>
−
</div>
+
        <div class="cuContent">
 +
<a target="_blank" href="https://2018.igem.org/Main_Page"><i class="fa fa-caret-right"></i>&#160;iGEM Main Page</a>
 +
<br/>
 +
<a target="_blank" href="https://2018.igem.org/Main_Page"><i class="fa fa-caret-right"></i>&#160;iGEM Special Pages</a>
 +
</div>
 +
</div>
 +
<img width="5%">
 +
<div class="cuCol" id="cuCol2" style="width: 17%;">
 +
<h1 class="cuH1"><i class="fa fa-envelope-o"></i>&#160;&#160;Email</h1>
 +
<hr width="50%">
 +
<br/>
 +
<div  class="cuContent">
 +
<a href="mailto:igem@fudan.edu.cn"><i class="fa fa-caret-right"></i>&#160;igem@fudan.edu.cn</a>
 +
<br/>
 +
<a href="mailto:kfjin16@fudan.edu.cn"><i class="fa fa-caret-right"></i>&#160;kfjin16@fudan.edu.cn</a>
 +
 +
<br/>
 +
</div>
 +
</div>
 +
<img width="5%">
 +
<div class="cuCol" id="cuCol3" style="width: 30%;">
 +
<h1 class="cuH1"><i class="fa fa-paper-plane"></i>&#160;&#160;Address</h1>
 +
<hr width="50%">
 +
<br/>
 +
<div  class="cuContent">
 +
G604, School of Life Sciences, Fudan University<br/>
 +
2005 Songhu Road, Yangpu, Shanghai, China
 +
</div>
 +
</div>
 +
<img id="cuTeamImg" src="https://static.igem.org/mediawiki/2018/f/fc/T--Fudan-CHINA--teamBadgeWhite.png"/>
 
</div>
 
</div>
 +
 +
<style>
 +
#contactUs{
 +
width: 100%;
 +
background: rgba(25,25,25,1);
 +
overflow: hidden;
 +
margin: 0;
 +
padding:1.5% 0 3% 0;
 +
text-align: left;
 +
position: relative;
 +
z-index: 100;
 +
}
 +
.cuCol{
 +
      display: inline-block;
 +
position: relative;
 +
left:20px;
 +
opacity: 0;
 +
color: rgba(168,168,168,1.00);
 +
text-align: left;
 +
vertical-align: top;
 +
}
 +
h1.cuH1{
 +
color: white;
 +
font-size: 1.4vw;
 +
font-style: normal;
 +
}
 +
.cuContent{
 +
font-family:Baskerville, "Palatino Linotype", Palatino, "Century Schoolbook L", "Times New Roman", "serif";
 +
font-size: 1.25vw;
 +
line-height: 1.6vw;
 +
}
 +
#contactUs a{
 +
color: rgba(168,168,168,1.00);
 +
text-decoration: none;
 +
}
 +
#contactUs a:hover{
 +
text-decoration: none;
 +
color:rgba(0,189,234,1);
 +
}
 +
#contactUs a:visited{
 +
text-decoration: none;
 +
}
 +
#contactUs a:active{
 +
text-decoration: none;
 +
}
 +
#contactUs br{
 +
line-height: 1vw;
 +
}
 +
#cuTeamImg{
 +
position: absolute;
 +
top:1vw;
 +
right:4vw;
 +
width: 10vw;
 +
opacity: 0.2;
 +
}
 +
</style>
 +
<script>
 +
slideInLeft($("#cuCol1"),$("#contactUs"),0);
 +
slideInLeft($("#cuCol2"),$("#contactUs"),150);
 +
slideInLeft($("#cuCol3"),$("#contactUs"),300);
 +
$(window).scroll(function(){
 +
slideInLeft($("#cuCol1"),$("#contactUs"),0);
 +
slideInLeft($("#cuCol2"),$("#contactUs"),150);
 +
slideInLeft($("#cuCol3"),$("#contactUs"),300);
 +
});
 +
</script>
 +
 +
<style>
 +
.leftNav{
 +
position: absolute;
 +
top:30vw;
 +
left: 2vw;
 +
list-style: none;
 +
z-index: 3;
 +
}
 +
.leftNav .leftNavA2{
 +
position: relative;
 +
}
 +
.leftNav .leftNavA2:before {
 +
    content: "";
 +
  display: inline-block;
 +
width: 5px;
 +
height: 5px;
 +
  background-color: rgba(55,55,62,0.7);
 +
    border-radius: 50%;
 +
position: absolute;
 +
left: 0.3vw;
 +
top:50%;
 +
margin: 0;
 +
padding: 0;
 +
transform: translateY(-50%);
 +
}
 +
.leftNavUl2{
 +
list-style: none;
 +
}
 +
.leftNavA{
 +
display: block;
 +
font-size: 1.3vw;
 +
font-family: Gotham, "Helvetica Neue", Helvetica, Arial, "sans-serif";
 +
padding: 0.5vw 1.5vw;
 +
color: #ffa400;
 +
text-decoration: none;
 +
}
 +
.leftNavLi2{
 +
width: 16vw;
 +
margin:0.5vw  0;
 +
line-height: 17px;
 +
}
 +
.leftNavA:visited{
 +
text-decoration: none;
 +
color: #ffa400;
 +
}
 +
.leftNavA:focus{
 +
text-decoration: none;
 +
color: #ffa400;
 +
}
 +
.leftNavA:hover,.leftNavA:active{
 +
text-decoration: none;
 +
color: #734a00;
 +
}
 +
 +
.leftNavA2{
 +
display: block;
 +
font-size: 1.1vw;
 +
font-family:Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";
 +
padding: 0.1vw 1.5vw;
 +
color:rgba(168,168,168,1);
 +
text-decoration: none;
 +
}
 +
.leftNavA2:visited{
 +
text-decoration: none;
 +
color:rgba(168,168,168,1);
 +
}
 +
.leftNavA2:focus{
 +
text-decoration: none;
 +
color:rgba(168,168,168,1);
 +
}
 +
.leftNavA2:hover,.leftNavA2:active{
 +
text-decoration: none;
 +
color: rgba(35,35,35,1);
 +
}
 +
.menu-active,.menu-active:focus{
 +
text-decoration: none;
 +
color: rgba(35,35,35,1);
 +
text-decoration: none;
 +
}
 +
</style>
 +
<script>
 +
 +
var winHeight=$(window).height();
 +
var winWidth=$(window).width();
 +
$(".leftNav").css({"position":"absolute","top":0.3*winWidth});
 +
$(window).resize(function(){
 +
var winHeight=$(window).height();
 +
var winWidth=$(window).width();
 +
var leftNavFromTop=0.3*winWidth-$(window).scrollTop();
 +
if (leftNavFromTop<0.1*winWidth){
 +
$(".leftNav").css({"position":"fixed","top":0.1*winWidth});
 +
}
 +
else{
 +
$(".leftNav").css({"position":"absolute","top":0.3*winWidth});
 +
}
 +
});
 +
 +
$(window).scroll(function(){
 +
var winHeight=$(window).height();
 +
var winWidth=$(window).width();
 +
var leftNavFromTop=0.3*winWidth-$(window).scrollTop();
 +
if (leftNavFromTop<0.1*winWidth){
 +
$(".leftNav").css({"position":"fixed","top":0.1*winWidth});
 +
}
 +
else{
 +
$(".leftNav").css({"position":"absolute","top":0.3*winWidth});
 +
}
 +
});
 +
$(".leftNav a").click(function () {
 +
$('html, body').animate({
 +
scrollTop: $($.attr(this, 'href')).offset().top
 +
}, 500);
 +
return false;
 +
});
 +
 +
 +
    $(window).scroll(function(){
 +
var currentScroll=$(this).scrollTop();
 +
var $currentSection;
 +
var firstHeight=$("#firstDiv").height();
 +
$('.leftNavA2').each(function(){
 +
var hePoint=$($(this).attr("href"));
 +
var divPosition=hePoint.offset().top;
 +
if (divPosition-1<currentScroll){
 +
$currentSection=$(this);
 +
}
 +
if (currentScroll>firstHeight){
 +
                $('.leftNavA2').removeClass('menu-active');
 +
                $currentSection.addClass('menu-active');
 +
}
 +
})
 +
});
 +
 +
</script>
 +
 +
 +
<style>
 +
#firstDiv{
 +
width: 100%;
 +
height: 22vw;
 +
overflow: hidden;
 +
position: relative;
 +
z-index: 5;
 +
}
 +
#firstDiv img{
 +
filter: brightness(0.6);
 +
position: relative;
 +
width: 101%;
 +
top:50%;
 +
left:50%;
 +
transform: translateX(-50%) translateY(-53%);
 +
}
 +
    .fiName{
 +
color: white;
 +
font-family:Allura,_Allura;
 +
font-size: 5vw;
 +
font-weight: 600;
 +
position: absolute;
 +
top:15vw;
 +
right: 12vw;
 +
}
 +
.pSentence{
 +
color: white;
 +
font-family:Baskerville, "Palatino Linotype", Palatino, "Century Schoolbook L", "Times New Roman", "serif";
 +
font-size: 1.2vw;
 +
font-weight: 400;
 +
position: absolute;
 +
top:18vw;
 +
right: 12vw;
 +
text-align: right;
 +
}
 +
</style>
  
  
 +
<style>
 +
.theAnchor{
 +
position: absolute;
 +
top:-25vh;
 +
}
 +
.mainWords{
 +
margin-left: 15vw;
 +
margin-top: 136px;
 +
margin-bottom: 85px;
 +
margin-right: 15vw;
 +
background-color: white;
 +
}
 +
a.contentLink,.contentLink:hover,.contentLink:focus,.contentLink:active,.contentLink:visited{
 +
text-decoration: none;
 +
}
 +
a.contentLink{
 +
font-weight: 900;
 +
font-family: "Quicksand Medium",_Quicksand;
 +
color:rgba(130,166,245,1);
 +
}
 +
a.contentLink:hover{
 +
color:royalblue;
 +
}
 +
 +
.mainTitle1{
 +
margin:100px 0;
 +
font-family:"Verlag Book",_VerlagBook,Arial,Helvetica;
 +
font-size: 40px;
 +
text-transform:uppercase;
 +
color:rgba(29,176,186,1);
 +
position: relative;
 +
}
 +
.mainTitle1:before{
 +
content: "";
 +
width: 340px;
 +
height: 3.4px;
 +
background:rgba(29,176,186,1);
 +
display: inline-block;
 +
position: absolute;
 +
top:54px;
 +
}
 +
.mainTitle2{
 +
font-family:"Lucida Grande", "Lucida Sans Unicode", "Lucida Sans", "DejaVu Sans", Verdana, "sans-serif";
 +
font-size: 34px;
 +
color: rgba(73,90,128,1);
 +
margin: 10px 0 25px 0;
 +
position: relative;
 +
}
 +
.mainTitle3{
 +
font-family: Gotham, "Helvetica Neue", Helvetica, Arial, "sans-serif";
 +
font-size: 25px;
 +
color: black;
 +
margin-bottom: -15px;
 +
margin-top: 70px;
 +
}
 +
.mainContents{
 +
font-family:_Bembo,Cambria, "Hoefler Text", "Liberation Serif", Times, "Times New Roman", "serif";
 +
font-size: 21px;
 +
line-height: 28px;
 +
color: rgba(1,5,15,1.00);
 +
text-align:justify;
 +
margin-bottom: 85px;
 +
}
 +
.centerImg{
 +
width:50%;
 +
transform: translateX(-50%);
 +
position: relative;
 +
left:50%;
 +
}
 +
.mainContents span.bf{
 +
font-weight: 900;
 +
}
 +
.imgState{
 +
text-align: center;
 +
margin: 2vw 0;
 +
}
 +
.imgState>img{
 +
width: 40%;
 +
margin: 0 30px;
 +
}
 +
.figureNum{
 +
font-weight: 600;
 +
font-size:15px;
 +
font-family: Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";
 +
}
 +
.legend{
 +
font-size:15px;
 +
font-family: Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";
 +
}
 +
.imgState>div{
 +
font-family: Segoe, "Segoe UI", "DejaVu Sans", "Trebuchet MS", Verdana, "sans-serif";
 +
font-size: 17px;
 +
margin: 20px 0;
 +
}
 +
.duanjian{
 +
margin: 5px 0;
 +
display: inline-block;
 +
}
 +
</style>
 +
 +
  
  

Latest revision as of 07:02, 30 November 2018

Applied Design
"What we do for ourselves dies with us. What we do for others and the world remains and is immortal."
Our project provides a brand-new solution for cell therapy of cancer – to deal with free extracellular ligands instead of cell surface antigens, which are obviously difficult to reach because of the barrier of tumour microenvironment.

For clinical application, the STEP system can be used to equip cells for cancer therapy. Stable STEP cell line can be produced with T cells extracted from patients. Then it can be reinfused into the blood to monitor level of target ligand and to produce specific drug in real time (Figure 1). In this way we can release patients from the pain of radiotherapy or chemotherapy, while inhibit tumour development in a more efficient way.
Figure 1.

One of the biggest advantage STEP has over other treatments is its modifiable upstream and downstream. For ligand recognition, we’ve already developed STEP for VEGF and for D-Dimer, the former for broad-spectrum scanning for tumour and the latter more specific for NSCLC. Both systems will be ready to use after overall test and optimisation in T cells. Our users can also select one or more tumour marker for a particular cancer type, clone the scFv or other kinds of binding domains to the extracellular domain and test the output. The binding affinity can always be increased, or in some cases decreased, with the help of our user-friendly assistant software and Rosetta. If there’s no sequence of binding domain available, we can also help you design a high-affinity scFv in silico with these softwares (Figure 2). As a result, we can literally achieve recognisation of any customer appointed ligands with our STEP system.
Figure 2.

Another superiority of STEP is the tuneable downstream and the changeable reporter. The curve of downstream gene expression can be easily modified either by simply changing a transcription factor, or by altering the binding affinity between the DNA sequence and the transcription factor. The reporter, on the other hand, can be any kind of drugs for unique situations of different patients.

Being a highly modular transducer engineering platform and able to meet needs of various kinds of cancer patients, STEP will definitely be the best choice for cell therapy.

  Address


G604, School of Life Sciences, Fudan University
2005 Songhu Road, Yangpu, Shanghai, China